Bristol Myers Squibb Co $50.65

up +0.11


29/8/2014 04:00 PM  |  NYSE : BMY  
Industries : Drugs / Drug Manufacturers - Major
Get Trend Analysis Icon Get BMY Trend Analysis - it has underperformed the S&P 500 by 1%

Partner Headlines

  1. Bristol-Myers: Absolute Valuation Model versus Relative Valuation Model

    GuruFocus
  2. Bristol-Myers Drug Gets OK

    IBD
  3. Markets Little Changed In Low Volume And Slow News Ahead Of Long Weekend

    Benzinga
  4. Deutsche Bank Starts Pfizer, Lilly at Buy, Merck, Bristol-Myers at Hold

    Benzinga
  5. Bristol-Myers Hepatitis C Therapy Approved in EU

    IBD
  6. US Stock Futures Edge Higher Ahead Of Tiffany Earnings

    Benzinga
  7. Merck, Pfizer Combining Drugs In Lung Cancer Study

    IBD
  8. Intercept Pharma Soars On Liver-Disease Drug Data

    IBD
  9. Markets Marginally Higher On Light Volume And Encouraging Geopolitical ...

    Benzinga
  10. Drugmaker AstraZeneca Returns To Growth

    IBD
  11. The Stocks Already in Correction Mode

    FoxBusiness
  12. Will ImmunoGen's Q4 Earnings Disappoint Again?

    GuruFocus
  13. Bristol-Myers surprises Street

    IBD
  14. Thursday Morning Earnings Reports

    Benzinga
  15. Stock Futures Steer Higher; Facebook, Skechers Nail Q2 Wins

    IBD
  16. Earnings Scheduled For July 24, 2014

    Benzinga
  17. Facebook, Gilead Headline IBD 50's Top 5 Earnings

    IBD
  18. Benzinga Weekly Preview: Earnings Season Continues With Geopolitical Tensions ...

    Benzinga
  19. UnitedHealth Group Up on Weak Day for the Dow

    GuruFocus
  20. Dow Sets New Intraday High; Citigroup Impresses With Earnings

    Benzinga
  21. Senators Ask Gilead To Explain Sovaldi Pricing

    IBD
  22. Bristol seeks cancer drug nod

    IBD
  23. Bristol-Myers Seeking Nivolumab Approval In Melanoma

    IBD
  24. Japan approves BMY regimen

    IBD
  25. Jazz, Novo Among Medicals Showing Healthy Action

    IBD
  26. Bristol-Myers' All-Oral HCV Therapy Approved In Japan

    IBD
  27. Merck, Gilead Lead Race To Eradicate Hepatitis C

    IBD
  28. Markets Little Changed Ahead Of 4th Of July Break

    Benzinga
  29. Barclays Downgrades Pharmaceutical Sector

    Benzinga
  30. UPDATE: Barclays Downgrades Bristol-Myers, Cuts Price Target By 41%

    Benzinga
  31. Benzinga's Top Downgrades

    Benzinga
  32. Ex-Dividends For July 1, 2014

    Benzinga
  33. Pfizer and others get EU nods

    IBD
  34. Bristol-Myers, Pfizer, Regeneron Drugs Get EU Nods

    IBD
  35. Pfizer, Bristol-Myers Squibb Announce Positive Opinion For Treatments

    Benzinga
  36. US Stock Futures Drop Ahead Of Consumer Sentiment Report

    Benzinga
  37. Bristol-Myers Squibb Receives Positive CHMP Opinion for Daklinza for Treatment ...

    Benzinga
  38. Pharma Sector Stocks To Consider For Sustained Returns

    GuruFocus
  39. Bristol-Myers Stock Up On Nivolumab Trial Success

    IBD
  40. BRISTOL-MYERS SQUIBB

    IBD
  41. UPDATE: Bristol Myers Announces Phase 3 First-Line Study of Nivolumab Stopped ...

    Benzinga
  42. Benzinga's M&A Chatter for Monday June 16, 2014

    Benzinga
  43. Merck Takes The 'Nuc' Option In Hepatitis C Race

    IBD
  44. ASCO Meeting Day 4: Risks And Rewards Of Immunotherapy

    Benzinga
  45. ASCO Meeting Day 3: Do More Treatments Equal A Longer Life?

    Benzinga
  46. Bristol-Myers Offers Two-, Three-Year Survival Data for Nivolumab

    Benzinga
  47. AstraZeneca Woos Shareholders With Promise Of Growth

    IBD
  48. Vanguard Health Care Fund's Top Quarterly Holdings

    GuruFocus
  49. Bristol, Merck Q1 sales soft

    IBD
  50. Bristol, Merck, Sanofi Report Soft Q1 Sales

    IBD
Trading Center